会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明授权
    • Pyrrolobenzimidazoles and pharmaceutical compositions containing them
    • 吡咯并苯并咪唑和含有它们的药物组合物
    • US4863945A
    • 1989-09-05
    • US131367
    • 1987-12-10
    • Walter-Gunar FriebeAlfred MertensKlaus StreinErwin Boehm
    • Walter-Gunar FriebeAlfred MertensKlaus StreinErwin Boehm
    • A61K31/40A61P7/02A61P9/04A61P9/12C07D487/04
    • C07D487/04
    • Pyrrolobenzimidazoles of the formula: ##STR1## are useful for treatment of heart and circulatory diseases. R.sub.1 is substituted phenyl; or optionally substituted naphthyl or a five- or six-membered heterocyclic group which can be condensed with a phenyl ring to form a bicyclic radical. R.sub.2 is hydrogen, alkyl, alkenyl or cycloalkenyl; R.sub.3 is alkyl, alkenyl or hydroxyalkyl or with R.sub.2 together forms cycloakylene; or R.sub.2 and R.sub.3 together form alkylidene or cycloalkylidene. R.sub.4 is hydrogen or lower alkanoyl. X is a valency bond, alkylene, vinylene, imino or carbonylamino. T stands for two hydrogen atoms. When X is a valency bond, R.sub.1 can also be hydrogen, hydrocarbyl which may also contain oxygen, amino, sulfur, carbonyl and sulfonyl groups. When X is imino or carbonylamino or when R.sub.1 is a bicyclic radical, T can also be oxygen. The compounds also include the tautomers and physiologically acceptable salts with inorganic and organic acids.
    • 下式的吡咯并苯并咪唑:可用于治疗心脏和循环系统疾病。 R1是取代的苯基; 或任选取代的萘基或可与苯环缩合形成双环基团的五元或六元杂环基。 R2是氢,烷基,烯基或环烯基; R3是烷基,烯基或羟基烷基或与R2一起形成亚环烷基; 或者R 2和R 3一起形成亚烷基或亚环烷基。 R4是氢或低级烷酰基。 X是价键,亚烷基,亚乙烯基,亚氨基或羰基氨基。 T代表两个氢原子。 当X是价键时,R 1也可以是氢,也可以含有氧,氨基,硫,羰基和磺酰基的烃基。 当X是亚氨基或羰基氨基时,或当R1是双环基时,T也可以是氧。 化合物还包括与无机和有机酸形成的互变异构体和生理上可接受的盐。
    • 10. 发明授权
    • Heterocyclic-substituted indoles and pharmaceutical compositions
containing them
    • 杂环取代的吲哚和含有它们的药物组合物
    • US4851406A
    • 1989-07-25
    • US904092
    • 1986-09-04
    • Alfred MertensWolfgang von der SaalWalter-Gunar FriebeBernd Muller-BeckmannGisbert Sponer
    • Alfred MertensWolfgang von der SaalWalter-Gunar FriebeBernd Muller-BeckmannGisbert Sponer
    • C07D409/14A61K31/44A61K31/4427A61K31/4433A61K31/445A61K31/50A61K31/53A61K31/535A61P9/00C07D237/00C07D333/00C07D401/14C07D403/04C07D403/14C07D413/14C07D417/14
    • C07D401/14
    • The present invention provides indole derivatives of the general formula: ##STR1## wherein R.sub.1 is a hydrogen atom or an alkyl, alkenyl, cycloalkyl, cycloalkenyl, carboxyl, cyano, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl or aryl radical, R.sub.2 is a hydrogen atom or an alkyl, trihalogenomethyl, hydroxyl, cycloalkyl, cyano, carboxyl, alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl radical; R.sub.2 is a heterocyclic five-membered ring containing 1 to 4 heteroatoms or a heterocyclic six-membered ring containing 1 to 5 heteroatoms, the heteroatoms of the five- and six-membered rings being the same or different and being nitrogen, oxygen or sulphur and one or more of the nitrogen atoms optionally carrying an oxygen atom, the said five- and six-membered rings optionally being substituted by one or more alkyl, alkoxy, alkylthio, oxo, hydroxyl, nitro, amino, halogen or cyano groups; or R.sub.2 is ##STR2## the tautomers thereof and the physiologically acceptable salts thereof with inorganic and organic acids.The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them.Furthermore, the present invention provides intermediates of the general formula: ##STR3## in which R.sub.1, R.sub.2, A and X have the same meanings as above, and processes for the preparation of these intermediates.
    • 本发明提供以下通式的吲哚衍生物:其中R 1是氢原子或烷基,烯基,环烷基,环烯基,羧基,氰基,烷基羰基,烷氧基羰基,氨基羰基,烷基氨基羰基,二烷基氨基羰基或芳基, R2是氢原子或烷基,三卤代甲基,羟基,环烷基,氰基,羧基,烷氧基羰基,烷基羰基,氨基羰基,烷基氨基羰基或二烷基氨基羰基; R2是含有1至4个杂原子的杂环五元环或含有1至5个杂原子的杂环六元环,五元和六元环的杂原子相同或不同,为氮,氧或硫, 一个或多个氮原子任选地带有氧原子,所述五元和六元环任选被一个或多个烷基,烷氧基,烷硫基,氧代,羟基,硝基,氨基,卤素或氰基取代; 或者R2是其互变异构体及其与无机和有机酸的生理上可接受的盐。 本发明还提供了制备这些化合物的方法和含有它们的药物组合物。 此外,本发明提供通式如下的中间体:其中R1,R2,A和X具有与上述相同的含义,以及制备这些中间体的方法。